Skip to main content
. 2009 Nov;11(6):583–589. doi: 10.2353/jmoldx.2009.090061

Table 2.

Correlation of KRAS2 Mutation Status between Bile and Serum of Four Patients with Biliary Tract Carcinoma

Location Bile Serum
Bil 15 Extrahepatic GAT (93.4%) GAT (3.2%)
GTT (1.2%) GTT (4.3%)
Bil 49 Extrahepatic AGT (<0.1%) Wild type
Bil 52 Gallbladder Wild type GAT (1.2%)
Bil 73 Intrahepatic GAT (3.5%) GAT (1.0%)
GTT (1.2%)
HHS Vulnerability Disclosure